PALM BEACH, Fla. – The first day of the National Association of Chain Drug Stores Annual Meeting got off to a fast start at a breakfast on GLP-1s sponsored by retailmediaIQ, publisher of Chain Drug Review and MMR. Building on a webinar devoted to the same topic earlier this year, the session addressed the latest developments in a rapidly evolving category that is poised to impact much of what transpires in the food and pharmacy sectors. Moderated by Parag Shah, co-founder, partner and chief growth officer at Think Blue, the panelists included Jim Kirby, chief commercial officer at Kroger Health, Betty Pio, a partner and strategic advisor to pharma and biotech at Kearney, and Sarah Squires, director of Retail Insights Drug Channel at NielsenIQ.
CDR/MMR breakfast at NACDS Annual looks at the latest developments in GLP-1 category
The session addressed the latest GLP-1 developments in a rapidly evolving category that is poised to impact much of what transpires in the food and pharmacy sectors.
Related
Video Forum: Colleen Lindholz, Kroger, and Aaron Wiese, Hy-Vee
The time is right to reimagine retail health.
NACDS Foundation welcomes new members to its board of directors
Directors from Unilever, Kroger Health, Inmar Intelligence, Haleon, Colgate-Palmolive, and Walmart to support the Foundation’s ongoing focus on research and education.
Jim Whitman honored with NACDS’ highest distinction: Sheldon W. Fantle Lifetime Achievement Award
This tribute was particularly significant as Jim has been instrumental in constantly transforming and sustaining the NACDS Annual Meeting and other NACDS meetings and conferences as premier events that foster industry relationships and drive advancement.
Latest
Senate finance leaders introduce bipartisan PBM Reform, NACDS hails move and calls for swift passage
Legislation aims to curtail harmful PBM middlemen tactics that inflate drug costs and force pharmacies to close.
NCPA urges Congress to pass Crapo-Wyden PBM Reforms
Wide bipartisan support means no more excuses, says NCPA.
Kroger Q3 earnings beat estimates
Gains in eCommerce and private-label brands offset charges tied to automated fulfillment network; grocer lifts earnings guidance for the year.
CVS Health to pay $37.76 million over insulin pen overbilling allegations
Settlement resolves decade-long False Claims Act violations tied to premature refills and inaccurate reporting to federal health care programs.